<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34901283</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2314-6141</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2021</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>BioMed research international</Title>
          <ISOAbbreviation>Biomed Res Int</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Effect of Letrozole Combined with Dydrogesterone for Endometriosis in China: A Meta-Analysis.</ArticleTitle>
        <Pagination>
          <StartPage>9946060</StartPage>
          <MedlinePgn>9946060</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">9946060</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2021/9946060</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To discuss the effects of dydrogesterone combined with letrozole on the effectiveness, sex hormone levels, and serological indicators in patients with endometriosis. This study is registered with PROSPERO (CRD42020213172).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We searched relevant randomized controlled trials (RCTs) through PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP Database. The standardized mean differences (SMDs), the mean differences (MDs), or odds ratios (ORs) with their 95% confidence intervals (95% CIs) were computed to be outcome indicators, including total effectiveness, Vascular Endothelial Growth Factor (VEGF) level, Carbohydrate Antigen 125 (CA125) level, Follicle-Stimulating Hormone (FSH) level, Luteinizing Hormone (LH) level, estrogen (E2) level, progesterone (P) level, interleukin-6 (IL-6) level, and tumor necrosis factor-a (TNF-a) level.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 19 RCTs involving 1,591 patients were included in this study. Our results showed that letrozole combined with dydrogesterone can significantly reduce the levels of VEGF (SMD -2.23, 95% CI -2.39 to -2.07; <i>p</i> &lt; 0.00001), CA125 (MD -10.53, 95% CI -11.19 to -9.88; <i>p</i> &lt; 0.00001), E2 (SMD -1.64, 95% CI -1.81 to -1.47; <i>p</i> &lt; 0.00001), P (MD -5.11, 95% CI -6.26 to -3.96; <i>p</i> &lt; 0.00001), IL-6 (MD -4.41, 95% CI -5.16 to -3.67; <i>p</i> &lt; 0.00001), and TNF-a (MD -5.67, 95% CI -6.34 to -5.00; <i>p</i> &lt; 0.00001) in patients with endometriosis compared with the control group. In addition, the results indicated that total effectiveness was significantly higher in the experiment group (OR 6.21, 95% CI 4.17 to 9.24; <i>p</i> &lt; 0.00001) compared to the control. However, there was no significant difference between FSH and LH levels in both groups (<i>p</i> &gt; 0.05).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This combination therapy can effectively decrease the levels of VEGF, CA125, E2, P, IL-6, and TNF-a and increase the total effectiveness when comparing with the control group.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Shumei Sun et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Shumei</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-4961-433X</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, 610000 Sichuan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hao</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>People's Hospital of Deyang City, Deyang, 618000 Sichuan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Peicheng</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0003-3382-8042</Identifier>
            <AffiliationInfo>
              <Affiliation>Huizhou Municipal Central Hospital, Huizhou, 516000 Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Zhihong</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0003-4829-3853</Identifier>
            <AffiliationInfo>
              <Affiliation>People's Hospital of Deyang City, Deyang, 618000 Sichuan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Biomed Res Int</MedlineTA>
        <NlmUniqueID>101600173</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>90I02KLE8K</RegistryNumber>
          <NameOfSubstance UI="D004394">Dydrogesterone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004394" MajorTopicYN="N">Dydrogesterone</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004715" MajorTopicYN="N">Endometriosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>18</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34901283</ArticleId>
        <ArticleId IdType="pmc">PMC8660186</ArticleId>
        <ArticleId IdType="doi">10.1155/2021/9946060</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Mehedintu C., Plotogea M. N., Ionescu S., Antonovici M. Endometriosis still a challenge. 
Journal of Medicine and Life
. 2014;7(3):349–357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4233437</ArticleId>
            <ArticleId IdType="pubmed">25408753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu Y., Yuan S., Wang H. Vitamin D status in endometriosis: a systematic review and meta-analysis. 
Archives of Gynecology and Obstetrics
. 2020;302(1):141–152. doi: 10.1007/s00404-020-05576-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00404-020-05576-5</ArticleId>
            <ArticleId IdType="pubmed">32430755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giudice L. C., Kao L. C. Endometriosis. 
Lancet
. 2004;364(9447):1789–1799. doi: 10.1016/S0140-6736(04)17403-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(04)17403-5</ArticleId>
            <ArticleId IdType="pubmed">15541453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiesel L., Sourouni M. Diagnosis of endometriosis in the 21st century. 
Climacteric
. 2019;22(3):296–302. doi: 10.1080/13697137.2019.1578743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/13697137.2019.1578743</ArticleId>
            <ArticleId IdType="pubmed">30905186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garalejić E., Bojović-Jović D., Damjanović A., et al.  Hamilton anxiety scale (HAMA) in infertile women with endometriosis and its correlation with magnesium levels in peritoneal fluid. 
Psychiatria Danubina
. 2010;22(1):64–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20305593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vercellini P., Viganò P., Somigliana E., Fedele L. Endometriosis: pathogenesis and treatment. 
Nature Reviews. Endocrinology
. 2014;10(5):261–275. doi: 10.1038/nrendo.2013.255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrendo.2013.255</ArticleId>
            <ArticleId IdType="pubmed">24366116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peiris A. N., Chaljub E., Medlock D. Endometriosis. 
JAMA
. 2018;320(24):p. 2608. doi: 10.1001/jama.2018.17953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2018.17953</ArticleId>
            <ArticleId IdType="pubmed">30575883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu J., Song H., Zhou M., et al.  Progesterone receptor modulators for endometriosis. 
Cochrane Database of Systematic Reviews
. 2017;2017(7, article D9881) doi: 10.1002/14651858.CD009881.pub2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD009881.pub2</ArticleId>
            <ArticleId IdType="pmc">PMC6483151</ArticleId>
            <ArticleId IdType="pubmed">28742263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavone M. E., Bulun S. E. Aromatase inhibitors for the treatment of endometriosis. 
Fertility and Sterility
. 2012;98(6):1370–1379. doi: 10.1016/j.fertnstert.2012.08.053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2012.08.053</ArticleId>
            <ArticleId IdType="pmc">PMC3513666</ArticleId>
            <ArticleId IdType="pubmed">22999792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrero S., Gillott D. J., Venturini P. L., Remorgida V. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. 
Reproductive Biology and Endocrinology
. 2011;9(1):p. 89. doi: 10.1186/1477-7827-9-89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1477-7827-9-89</ArticleId>
            <ArticleId IdType="pmc">PMC3141646</ArticleId>
            <ArticleId IdType="pubmed">21693038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y., Luan X., Wang Y. Letrozole combined with oral contraceptives versus oral contraceptives alone in the treatment of endometriosis-related pain symptoms: a pilot study. 
Gynecological Endocrinology
. 2021;37(1):51–55. doi: 10.1080/09513590.2020.1807502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09513590.2020.1807502</ArticleId>
            <ArticleId IdType="pubmed">32936010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schweppe K. W. The place of dydrogesterone in the treatment of endometriosis and adenomyosis. 
Maturitas
. 2009;65(Suppl 1):S23–S27. doi: 10.1016/j.maturitas.2009.11.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.maturitas.2009.11.011</ArticleId>
            <ArticleId IdType="pubmed">19945806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins J. P. T.  
Cochrane Handbook for Systematic Reviews of Interventions
. 2nd. The Cochrane Collaboration; 2020. </Citation>
        </Reference>
        <Reference>
          <Citation>Lian J. M. Effects of didrogesterone combined with letrozole on Kupperman score, ALDH1 level and ovarian reserve function in patients with endometriosis (in Chinese) 
China Licensed Pharmacist
. 2020;17:35–39.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang J. Effects of dydrogesterone combined with letrozole on hormone levels and serum VEGF levels in patients with endometriosis (in Chinese) 
Henan Medical Research
. 2020;29:297–298.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang J., Liu Y., Liu F. X. Effect of desdrogesterone combined with letrozole on serum carbohydrate antigen 125 level and recurrence rate in patients with endometriosis (in Chinese) 
China Journal of Pharmaceutical Economics
. 2019;14:108–110.</Citation>
        </Reference>
        <Reference>
          <Citation>Xie A. L. Effects of dydrogesterone combined with letrozole on estrogen and progesterone and VEGF levels in patients with endometriosis (in Chinese) 
Henan Medical Research
. 2019;28:3726–3728.</Citation>
        </Reference>
        <Reference>
          <Citation>Li X. Z., Liu X. M. Study on the value of dydrogesterone combined with letrozole in the treatment of endometriosis (in Chinese) 
The Department of Oral Medicine Electronic Magazine(Electronic Edition)
. 2019;6:177–178.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu Z. J. Analysis of the effect of desorgestrel combined with letrozole in the treatment of endometriosis (in Chinese) 
Inner Mongolia Medical Journal
. 2019;51:914–916.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao Y. Z. Effects of dydrogesterone combined with letrozole on sex hormones and menstruation in patients with endometriosis (in Chinese) 
Clinical Research
. 2019;27:88–89.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang W. Clinical efficacy of treatment with triproterone combined with letrozole in the treatment of endometriosis (in Chinese) 
Journal of Practical Gynecologic Endocrinology
. 2019;6:142–145.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang L. N. Clinical efficacy of treatment with triproterone combined with letrozole in the treatment of endometriosis (in Chinese) 
Contemporary Medicine
. 2019;25:56–58.</Citation>
        </Reference>
        <Reference>
          <Citation>Bai Y. X. Clinical effect of dydrogesterone combined with letrozole in the treatment of endometriosis (in Chinese) 
Henan Medical Research
. 2019;28:1275–1277.</Citation>
        </Reference>
        <Reference>
          <Citation>Tan X. F., Li H. F., Wang Y. F., Gu Y. F. Effect of dydrogesterone combined with letrozole on sex hormones, inflammatory factors, CA125 and VEGF in patients with endometriosis (in Chinese) 
Basic &amp; Clinical Medicine
. 2019;39:392–395.</Citation>
        </Reference>
        <Reference>
          <Citation>Cao N. Observation on the effect of dydrogesterone combined with letrozole in the treatment of endometriosis (in Chinese) 
Medical Journal of Chinese People's Health
. 2018;30:35–37.</Citation>
        </Reference>
        <Reference>
          <Citation>Lian J. M. Effects of dydrogesterone combined with letrozole on serum sex hormones in patients with endometriosis (in Chinese) 
Inner Mongolia Medical Journal
. 2018;50:311–312.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen W. L. Effects of dydrogesterone combined with letrozole on serum sex hormone levels in patients with endometriosis (in Chinese) 
Clinical Medicine
. 2018;38:92–94.</Citation>
        </Reference>
        <Reference>
          <Citation>Hu Y. R. Efficacy of dydrogesterone and combined with letrozole on patients with endometriosis:the levels of E2, VEGF, and CA125 (in Chinese) 
Tibetan Journal of Medicine
. 2017;38:39–41.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen X. H. Clinical efficacy of treatment with triproterone combined with letrozole in the treatment of endometriosis (in Chinese) 
Healthmust-Readmagazine
. 2019;46</Citation>
        </Reference>
        <Reference>
          <Citation>Yue H. L. To explore the therapeutic effect of dydrogesterone combined with letrozole in patients with endometriosis (in Chinese) 
Special Health
. 2020;15:p. 55.</Citation>
        </Reference>
        <Reference>
          <Citation>Liang J. Effects of dydrogesterone combined with letrozole on VEGF and CA125 levels in patients with endometriosis (in Chinese) 
China Health Care &amp; Nutrition
. 2017;27:p. 366.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen J. L. Effects of dydrogesterone combined with letrozole on serum sex hormone, VEGF and CA125 levels in patients with endometriosis (in Chinese) 
Heilong Medical Jouranl
. 2020;44:1235–1236.</Citation>
        </Reference>
        <Reference>
          <Citation>Rolla E. Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment. 
F1000Res
. 2019;8 doi: 10.12688/f1000research.14817.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12688/f1000research.14817.1</ArticleId>
            <ArticleId IdType="pmc">PMC6480968</ArticleId>
            <ArticleId IdType="pubmed">31069056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sapkota Y., Steinthorsdottir V., Morris A. P., et al.  Meta-analysis identifies five novel loci associated with endometriosis highlighting key genes involved in hormone metabolism. 
Nature Communications
. 2017;8(1):p. 15539. doi: 10.1038/ncomms15539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms15539</ArticleId>
            <ArticleId IdType="pmc">PMC5458088</ArticleId>
            <ArticleId IdType="pubmed">28537267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nothnick W. B. The emerging use of aromatase inhibitors for endometriosis treatment. 
Reproductive Biology and Endocrinology
. 2011;9(1):p. 87. doi: 10.1186/1477-7827-9-87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1477-7827-9-87</ArticleId>
            <ArticleId IdType="pmc">PMC3135533</ArticleId>
            <ArticleId IdType="pubmed">21693036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almassinokiani F., Almasi A., Akbari P., Saberifard M. Effect of letrozole on endometriosis-related pelvic pain. 
Medical Journal of the Islamic Republic of Iran
. 2014;28:p. 107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4301232</ArticleId>
            <ArticleId IdType="pubmed">25664308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor P. J., Kredentser J. V. Nonsurgical management of minimal and moderate endometriosis to enhance fertility. 
International Journal of Fertility
. 1992;37(3):138–143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1355759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trivedi P., Selvaraj K., Mahapatra P. D., Srivastava S., Malik S. Effective post-laparoscopic treatment of endometriosis with dydrogesterone. 
Gynecological Endocrinology
. 2007;23(sup1):73–76. doi: 10.1080/09513590701669583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09513590701669583</ArticleId>
            <ArticleId IdType="pubmed">17943543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S., Xin X., Hua T., et al.  Efficacy of anti-VEGF/VEGFR agents on animal models of endometriosis: a systematic review and meta-analysis. 
PLoS One
. 2016;11(11, article e166658) doi: 10.1371/journal.pone.0166658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0166658</ArticleId>
            <ArticleId IdType="pmc">PMC5113963</ArticleId>
            <ArticleId IdType="pubmed">27855197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbieri R. L. CA-125 in patients with endometriosis. 
Fertility and Sterility
. 1986;45(6):767–769. doi: 10.1016/S0015-0282(16)49389-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0015-0282(16)49389-1</ArticleId>
            <ArticleId IdType="pubmed">2423377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muyldermans M., Cornillie F. J., Koninckx P. R. CA125 and endometriosis. 
Human Reproduction Update
. 1995;1(2):173–187. doi: 10.1093/humupd/1.2.173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/humupd/1.2.173</ArticleId>
            <ArticleId IdType="pubmed">15726771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F., Wang H., Jin D., Zhang Y. Serum miR-17, IL-4, and IL-6 levels for diagnosis of endometriosis. 
Medicine
. 2018;97(24, article e10853) doi: 10.1097/MD.0000000000010853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000010853</ArticleId>
            <ArticleId IdType="pmc">PMC6023682</ArticleId>
            <ArticleId IdType="pubmed">29901577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lyu J., Yang H., Lang J., Tan X. Tumor necrosis factor gene polymorphisms and endometriosis in Asians: a systematic review and meta-analysis. 
Chinese Medical Journal
. 2014;127(9):1761–1767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24791888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Y., Zhao M., Lin L., et al.  Is body mass index associated with the incidence of endometriosis and the severity of dysmenorrhoea: a case-control study in China? 
BMJ Open
. 2020;10(9, article e37095) doi: 10.1136/bmjopen-2020-037095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2020-037095</ArticleId>
            <ArticleId IdType="pmc">PMC7478014</ArticleId>
            <ArticleId IdType="pubmed">32895278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garalejic E., Arsic B., Radakovic J., et al.  A preliminary evaluation of influence of body mass index on in vitro fertilization outcome in non-obese endometriosis patients. 
BMC Womens Health
. 2017;17(1):p. 112. doi: 10.1186/s12905-017-0457-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12905-017-0457-0</ArticleId>
            <ArticleId IdType="pmc">PMC5691874</ArticleId>
            <ArticleId IdType="pubmed">29145852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colette S., Donnez J. Are aromatase inhibitors effective in endometriosis treatment? 
Expert Opinion on Investigational Drugs
. 2011;20(7):917–931. doi: 10.1517/13543784.2011.581226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/13543784.2011.581226</ArticleId>
            <ArticleId IdType="pubmed">21529311</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
